Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR.31 adjuvant durvalumab after resection of non-small cell lung cancer
ACTRN12615000323527Phase 3Completed
- Sponsor
- NHMRC Clinical Trials Centre
- Start
- Dec 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab with Placebo (2 arms). Primary endpoint: Disease-free survival in PD-L1 positive NSCLC. Started Dec 2015; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12615000323527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000323527.